Indivior Pharmaceuticals, Inc.'s latest marketcap:
As of 10/14/2026, Indivior Pharmaceuticals, Inc.'s market capitalization has reached $3.71 B. According to our data, Indivior Pharmaceuticals, Inc. is the 4578th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 3.71 B |
| Revenue (ttm) | 1.31 B |
| Net Income (ttm) | 349.12 M |
| Shares Out | 0 |
| EPS (ttm) | 2.71 |
| Forward PE | 7.56 |
| Ex-Dividend Date | 10/30/2026 |
| Earnings Date | 10/29/2026 |
Indivior Pharmaceuticals, Inc.'s yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|
Company Profile
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD).
The company also offers OPVEE nasal spray for opioid overdose reversal. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Frequently Asked Questions
-
What is Indivior Pharmaceuticals, Inc.'s (FRA-E7P) current market cap?As of 10/14/2026, Indivior Pharmaceuticals, Inc. (including the parent company, if applicable) has an estimated market capitalization of $3.71 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Indivior Pharmaceuticals, Inc. (FRA-E7P) rank globally by market cap?Indivior Pharmaceuticals, Inc. global market capitalization ranking is approximately 4578 as of 10/14/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.